Archives for 

Amgen v. Apotex (pegfilgrastim)

BPCIA Litigation Roundup (Summer 2017)

AbbVie v. Amgen (adalimumab)  •  AbbVie v. Boehringer Ingelheim (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Coherus (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Genentech v. Amgen (bevacizumab)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  Janssen v. Samsung Bioepis (infliximab)  •  U.S. Biosimilar Litigation News
Below is our summer update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, […]

View More

BPCIA Litigation Roundup (Spring 2017)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Coherus (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  Janssen v. Samsung Bioepis (infliximab)  •  U.S. Biosimilar Litigation News
Below is our spring update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, […]

View More

BPCIA Litigation Roundup (Midwinter 2017)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Genentech v. Amgen (bevacizumab)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News
Below is our midwinter update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, […]

View More

Year in Review: The Top-Five Legal Developments of 2016

Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Sandoz (filgrastim)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Patent Dance  •  PTAB + IPR  •  Reimbursement  •  Reimbursement  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions  •  U.S. Supreme Court Decisions
Here are our picks for the top-five most significant legal developments in the world of biosimilars in 2016: 5) Congress passed and President Obama signed the 21st Century Cures Act.  Among other things, […]

View More

BPCIA Litigation Roundup (Fall 2016)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News
Below is our Fall 2016 update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly update (Summer […]

View More